1 / 9

Tissue-Engineered Blood Vessel for Adult Arterial Revascularization

Tissue-Engineered Blood Vessel for Adult Arterial Revascularization. Robert Farley Biomedical Engineering. What are they?. Engineered blood vessels made from autologous cells Autologous cells – cells used to build the vessels are extracted from the patient

curran-horn
Download Presentation

Tissue-Engineered Blood Vessel for Adult Arterial Revascularization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tissue-Engineered Blood Vessel for Adult Arterial Revascularization Robert Farley Biomedical Engineering

  2. What are they? Engineered blood vessels made from autologous cells Autologous cells – cells used to build the vessels are extracted from the patient Fibroblasts and endothelial cells are harvestedfrom a small biopsy specimen of skin and superficial vein

  3. The specimen extracted is then combined with a method called sheet based tissue engineering SBTE is a method of tissue engineering where completely biological and living autologoustissues are used They have remarkable mechanical strength without theinclusion of any exogenous scaffolds

  4. Advantages Engineered vessels have the same strength thresholds as normal vessels No reason for rejection by the body No synthetic materials are used Will not move as shunts tend to do

  5. Study Objective of this study was to demonstrate thata tissue-engineered blood vessel produced in vitro could withstandthe challenges of arterial pressure produced by an arteriovenousfistula for a period of 90 days Ten patients receiving hemodialysis whose arteriovenous shuntswere failing were enrolled

  6. Patients had previouslyfailed dialysis-access grafts, diabetes, controlled hypertension and obesity Ranged in age from 29 to 89 years Patients underwent surgery where autologous vessels were implanted in place of the shunts Success of the vessel was measured using Doppler and angiographic imaging

  7. Results No evidence of vessel degradation Because of the age of some of the patients, they did not make it through the trial Death was unrelated to trial Remaining patients showed an increase in blood flow rate strength and of the connection involving the vessel

  8. Conclusion Few complications were noted after the 90 day trial 2 months after the trial, 3 of the patients still had no side effects Though the trial length was short, scientists and doctors involved in this study feel as though this is a milestone for cardiovascular engineering

  9. Sources Engineered Blood Vessel for Adult Arterial Revascularization." New England Journal of Medicine 1453rd ser. 357.1451 (2007). Web. <http://http://content.nejm.org/cgi/content/full/357/14/1451>. "Tissue Engineered Blood Vessel For Adult Arterial Revascularization." NIH 365th ser. 361 (2006). Web. 24 Apr. 2010. <http://http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513140/>.

More Related